Trial Profile
A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary)
- Indications Down syndrome
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2020 Results published in the Drugs in R and D
- 05 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.